US EditionIn Brief for May 14, 2025 - ILCN.org (ILCN/WCLC)
Summary by ILCN.org (ILCN/WCLC)
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
All
Left
Center
Right
In Brief for May 14, 2025 - ILCN.org (ILCN/WCLC)
Health Canada has approved the combination of pembrolizumab with chemotherapy for first-line treatment of unresectable advanced or metastatic malignant pleural mesothelioma (MPM). This represents Canada’s first approved pembrolizumab-chemotherapy combination regimen for patients with MPM. The decision was based on findings from the IND.227/KEYNOTE-483 trial, which revealed statistically significant improvements in overall survival (OS), overall …
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
Ownership
To view ownership data please Upgrade to Vantage
